A practical map for the company whose science is at the CROs. Where AI helps across clinical ops, regulatory, medical writing, and vendor oversight, and where the validated-environment line sits.
Read this if your bench is outsourced
Regulatory This map names where AI touches a clinical-ops company and where the validated-environment line sits, with the controlling regulations linked below. It is the shape of the constraint, not legal advice; confirm the specifics with your own quality and regulatory function.
Most AI-in-biotech advice pictures a discovery lab: assay data on your servers, models trained on your own experiments. If you run a clinical-stage company, that is not your company. Your science is largely at the CROs. The part with your employees and your deadlines is clinical operations, regulatory, medical writing, safety, and vendor oversight. This map is where AI touches that work, and where the validated-environment line sits.
Where AI helps today
Function
Where AI helps today
Medical writing and clinical study reports
First-draft narratives and summaries from structured data, consistency and style checks across a document set
Protocol and regulatory documents
Drafting and harmonizing protocols, consent forms, and submission summaries against templates and prior filings
Safety and pharmacovigilance narratives
Drafting case narratives from structured case data at volume, for human review before anything is filed
Regulatory submissions
Summarizing, drafting, and QC-ing content across submission modules, checking cross-references
Drafting queries, summarizing site performance, preparing for monitoring visits
Medical information and literature
Searching, summarizing, and drafting responses from public and licensed sources
The two lines that decide the environment
Two questions govern every use above, and neither is about the model.
First, what class of data. Patient data and results you have not yet filed are Tier 1, and they belong only in a contracted, enterprise-secure environment approved for that class, exactly as your AI Use Policy says. Public and non-confidential inputs are Tier 2, where you should push people to explore.
Second, is AI touching a validated record. There is a real difference between AI drafting a document a qualified human owns and reviews, and AI becoming part of a system that creates or maintains a GxP record. The first is mostly a People and Programs question: the human is the author of record, and your normal quality review still applies. The second is a computer-system-validation and 21 CFR Part 11 question, and it is your quality and regulatory function’s call, not something to route around.
Most of the early value sits on the near side of both lines: drafting and synthesis, on non-patient data or inside your approved environment, with a human who owns the output. There is more of it than you think.
Don’t relitigate the gates. Reconsider their shape.
The validated processes and review gates in a clinical-stage company were rational answers to a world where information was expensive to move and slow to trust. AI does not delete the judgment those gates protect, which is patient safety and data integrity, and you should not try. Do the Permission work once, choose controls you can stand behind, and stop relitigating settled safety debates out of principle.
But do ask the AI-native question. Is the current shape of a gate still the best way to protect what it guards, or is it a manual step that survived only because the old systems could not see each other. That is a question for you and your quality function together, answered deliberately, not a reason to wait.
Start where neither line bites: a first-draft narrative, a summarized monitoring report, a submission section a qualified human will own and check. Win there, bring your quality and regulatory function in early, and move the harder lines on purpose.
ICH, E6(R3) Good Clinical Practice (Step 4 reached January 2025; linked here as EMA’s Step 5 implementation), on computerised systems and data integrity in trials
## Read this if your bench is outsourced
<span class="ev ev--reg">Regulatory</span> This map names where AI touches a clinical-ops company and where the validated-environment line sits, with the controlling regulations linked below. It is the shape of the constraint, not legal advice; confirm the specifics with your own quality and regulatory function.
Most AI-in-biotech advice pictures a discovery lab: assay data on your servers, models trained on your own experiments. If you run a clinical-stage company, that is not your company. Your science is largely at the CROs. The part with your employees and your deadlines is clinical operations, regulatory, medical writing, safety, and vendor oversight. This map is where AI touches that work, and where the validated-environment line sits.
## Where AI helps today
| Function | Where AI helps today |
| --- | --- |
| Medical writing and clinical study reports | First-draft narratives and summaries from structured data, consistency and style checks across a document set |
| Protocol and regulatory documents | Drafting and harmonizing protocols, consent forms, and submission summaries against templates and prior filings |
| Safety and pharmacovigilance narratives | Drafting case narratives from structured case data at volume, for human review before anything is filed |
| Regulatory submissions | Summarizing, drafting, and QC-ing content across submission modules, checking cross-references |
| CRO and vendor oversight | Synthesizing monitoring reports, surfacing signals across vendor deliverables, drafting oversight questions |
| Clinical operations | Drafting queries, summarizing site performance, preparing for monitoring visits |
| Medical information and literature | Searching, summarizing, and drafting responses from public and licensed sources |
## The two lines that decide the environment
Two questions govern every use above, and neither is about the model.
*First, what class of data.* Patient data and results you have not yet filed are Tier 1, and they belong only in a contracted, enterprise-secure environment approved for that class, exactly as your [AI Use Policy](/artifacts/ai-use-policy/) says. Public and non-confidential inputs are Tier 2, where you should push people to explore.
*Second, is AI touching a validated record.* There is a real difference between AI drafting a document a qualified human owns and reviews, and AI becoming part of a system that creates or maintains a GxP record. The first is mostly a People and Programs question: the human is the author of record, and your normal quality review still applies. The second is a computer-system-validation and 21 CFR Part 11 question, and it is your quality and regulatory function's call, not something to route around.
Most of the early value sits on the near side of both lines: drafting and synthesis, on non-patient data or inside your approved environment, with a human who owns the output. There is more of it than you think.
## Don't relitigate the gates. Reconsider their shape.
The validated processes and review gates in a clinical-stage company were rational answers to a world where information was expensive to move and slow to trust. AI does not delete the judgment those gates protect, which is patient safety and data integrity, and you should not try. Do the Permission work once, choose controls you can stand behind, and stop relitigating settled safety debates out of principle.
But do ask the [AI-native](/ai-native-biotech/) question. Is the current shape of a gate still the best way to protect what it guards, or is it a manual step that survived only because the old systems could not see each other. That is a question for you and your quality function together, answered deliberately, not a reason to wait.
---
*Start where neither line bites: a first-draft narrative, a summarized monitoring report, a submission section a qualified human will own and check. Win there, bring your quality and regulatory function in early, and move the harder lines on purpose.*
<div class="ti-sources">
## Sources
- FDA and EMA, [Guiding Principles of Good AI Practice in Drug Development](https://www.fda.gov/media/189581/download) (January 2026), ten joint principles spanning the medicine lifecycle, from research through manufacturing and safety monitoring ([EMA announcement](https://www.ema.europa.eu/en/news/ema-fda-set-common-principles-ai-medicine-development-0))
- FDA, [21 CFR Part 11, Electronic Records; Electronic Signatures](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11) (eCFR, current)
- FDA, [Considerations for the Use of AI to Support Regulatory Decision-Making for Drug and Biological Products](https://www.federalregister.gov/documents/2025/01/07/2024-31542/considerations-for-the-use-of-artificial-intelligence-to-support-regulatory-decision-making-for-drug) (draft guidance, Federal Register, January 2025)
- ICH, [E6(R3) Good Clinical Practice](https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r3-guideline-good-clinical-practice-gcp-step-5_en.pdf) (Step 4 reached January 2025; linked here as EMA's Step 5 implementation), on computerised systems and data integrity in trials
- EMA, [Reflection paper on the use of AI in the medicinal product lifecycle](https://www.ema.europa.eu/en/use-artificial-intelligence-ai-medicinal-product-lifecycle-scientific-guideline) (2024)
</div>